Roni Appel Net Worth

The estimated Net Worth of Roni Appel is at least $147 mil dollars as of 11 March 2020. Mr. Appel owns over 3,000 units of Ayala Pharmaceuticals stock worth over $210 and over the last 19 years he sold ADXS stock worth over $1,710. In addition, he makes $144,615 as Independent Director at Ayala Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Appel ADXS stock SEC Form 4 insiders trading

Roni has made over 5 trades of the Ayala Pharmaceuticals stock since 2005, according to the Form 4 filled with the SEC. Most recently he sold 3,000 units of ADXS stock worth $1,710 on 11 March 2020.

The largest trade he's ever made was buying 1,238,095 units of Ayala Pharmaceuticals stock on 31 December 2005 worth over $247,619. On average, Roni trades about 56,084 units every 225 days since 2005. As of 11 March 2020 he still owns at least 10,476 units of Ayala Pharmaceuticals stock.

You can see the complete history of Mr. Appel stock trades at the bottom of the page.

Roni Appel biography

Roni A. Appel serves as Independent Director of the Company. He was our President and Chief Executive Officer from January 1, 2006 until December 2006 and Secretary and Chief Financial Officer from November 2004 to September 2006. From December 15, 2006 to December 2007, Mr. Appel served as a consultant to us. Mr. Appel currently is a self-employed consultant and the Co-Founder and President of Spirify Pharma Inc. Previously, he served as Chief Executive Officer of Anima Biotech Inc., from 2008 through January 31, 2013. From 1999 to 2004, he was a partner and managing director of LV Equity Partners (f/k/a LibertyView Equity Partners). From 1998 until 1999, he was a director of business development at Americana Financial Services, Inc. From 1994 to 1996, he worked as an attorney. Mr. Appel holds an M.B.A from Columbia University (1998) and an LL.B. from Haifa University (1994). Mr. Appel’s longstanding service with us and his entrepreneurial investment career in early stage biotech businesses qualify him to serve as our director.

What is the salary of Roni Appel?

As the Independent Director of Ayala Pharmaceuticals, the total compensation of Roni Appel at Ayala Pharmaceuticals is $144,615. There are 4 executives at Ayala Pharmaceuticals getting paid more, with Kenneth A. Berlin J.D. having the highest compensation of $1,162,449.

How old is Roni Appel?

Roni Appel is 53, he's been the Independent Director of Ayala Pharmaceuticals since 2006. There are 8 older and 1 younger executives at Ayala Pharmaceuticals. The oldest executive at Ayala Pharmaceuticals Inc. is Richard Berman, 77, who is the Independent Director.

What's Roni Appel's mailing address?

Roni's mailing address filed with the SEC is 305 COLLEGE ROAD EAST, , PRINCETON,, NJ, 08540.

Insiders trading at Ayala Pharmaceuticals

Over the last 20 years, insiders at Ayala Pharmaceuticals have traded over $12,060,930 worth of Ayala Pharmaceuticals stock and bought 7,108,817 units worth $19,940,745 . The most active insiders traders include Biotech Fund I, L.P.Israel ..., Capital Partners Gp, L.L.C.... y Thomas A Moore. On average, Ayala Pharmaceuticals executives and independent directors trade stock every 107 days with the average trade being worth of $12,473. The most recent stock trade was executed by Biotech Fund I, L.P.Israel ... on 7 February 2024, trading 27,847,159 units of ADXS stock currently worth $11,138,864.

What does Ayala Pharmaceuticals do?

advaxis (nasdaq: adxs) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. the advaxis technology, using bioengineered live attenuated bacteria, listeria monocytogenes (lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.

Complete history of Mr. Appel stock trades at Ayala Pharmaceuticals

Ayala Pharmaceuticals executives and stock owners

Ayala Pharmaceuticals executives and other stock owners filed with the SEC include:

• Kenneth A. Berlin J.D.,
  Pres, Interim CFO, CEO & Director
• Kenneth Berlin,
  President, Chief Executive Officer, Interim Chief Financial Officer, Director
• Andres Gutierrez,
  Chief Medical Officer and Executive Vice President
• Dr. Andres A. Gutierrez M.D., Ph.D.,
  Exec. VP & Chief Medical Officer
• Roni Appel,
  Independent Director
• David Sidransky,
  Independent Chairman of the Board
• James Patton,
  Independent Non-Executive Vice Chairman of the Board
• Tim McCarthy,
  Investor Relations
• Samir Khleif,
  Independent Director
• Richard Berman,
  Independent Director
• Igor Gitelman CPA, CPA, M.B.A., MBA,
  Chief Accounting Officer & VP of Fin.
• Gregory T. Mayes,,
  Chief Operating Officer
• Robert J. Spiegel,
  Director
• Robert Petit,
  Chief Scientific Officer
• Sara Bonstein,
  Chief Financial Officer
• Thomas J Mckearn,
  Director
• Thomas J Ridge,
  Director
• Murray A Goldberg,
  Director
• Biotech Fund I, L.P.Israel ...,
  
• Capital Partners Gp, L.L.C....,
  
• Anthony A Lombardo,
  Interim CEO
• Molly Henderson,
  Executive Vice President & CFO
• Fredrick D Cobb,
  Vice President Finance
• John F Rothman,
  VP of Clinical Development
• David J Mauro,
  Chief Medical Officer
• Daniel J. O'connor,
  SVP, Legal & Business Dev Off
• Thomas A Moore,
  Director
• Christy Lee French,
  Exec. Dir. of Medical Affairs
• Mark J Rosenblum,
  Chief Financial Officer
• Biotech Fund I, L.P.Israel ...,
  
• Growth Fund Limited Partner...,
  10% owner
• Vered Bisker Leib,
  Director